Selectively inhibiting PKM2 starves cancer cells

January 23, 2012

Crippling a protein that allows cancer cells to grow when oxygen is scarce causes tumors to regress, according to a study published online on January 23 in the Journal of Experimental Medicine.

An enzyme called PKM2 (M2 isoform of pyruvate ) is ramped up in cancer cells, allowing them to generate energy in the harsh, low-oxygen environment found within tumors.

Michael Goldberg and Phillip Sharp at the Massachusetts Institute of Technology now find that inhibiting PKM2 kills by starving them of energy but leaves normal cells unscathed. Crippling PKM2 caused established tumors in mice to melt away. If these results hold true in humans, this strategy could prove effective against a wide spectrum of cancers with minimal side effects.

Explore further: Understanding cancer energetics

More information: Goldberg, M.S., and P.A. Sharp. 2012. J. Exp. Med. doi:10.1084/jem.20111487

Related Stories

Understanding cancer energetics

June 4, 2011

(Medical Xpress) -- It's long been known that cancer cells eat a lot of sugar to stay alive. In fact, where normal, noncancerous cells generate energy from using some sugar and a lot of oxygen, cancerous cells use virtually ...

Recommended for you

Study: Enhancing cancer response to radiation

December 2, 2016

OHSU researcher Sudarshan Anand, Ph.D., has a contemporary analogy to describe microRNA: "I sometimes compare MicroRNA to tweets—they're short, transient and constantly changing."

Rare childhood disease linked to major cancer gene

December 1, 2016

A team of researchers led by a University of Rhode Island scientist has discovered an important molecular link between a rare childhood genetic disease, Fanconi anemia, and a major cancer gene called PTEN. The discovery improves ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.